These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 23213309)

  • 1. Mucosal Immune System and M Cell-targeting Strategies for Oral Mucosal Vaccination.
    Kim SH; Lee KY; Jang YS
    Immune Netw; 2012 Oct; 12(5):165-75. PubMed ID: 23213309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The M cell-targeting ligand promotes antigen delivery and induces antigen-specific immune responses in mucosal vaccination.
    Kim SH; Seo KW; Kim J; Lee KY; Jang YS
    J Immunol; 2010 Nov; 185(10):5787-95. PubMed ID: 20952686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Application of an M-cell-targeting ligand for oral vaccination induces efficient systemic and mucosal immune responses against a viral antigen.
    Kim SH; Jung DI; Yang IY; Jang SH; Kim J; Truong TT; Pham TV; Truong NU; Lee KY; Jang YS
    Int Immunol; 2013 Nov; 25(11):623-32. PubMed ID: 23900425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New generation of mucosal adjuvants for the induction of protective immunity.
    Yuki Y; Kiyono H
    Rev Med Virol; 2003; 13(5):293-310. PubMed ID: 12931340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted Delivery of VP1 Antigen of Foot-and-mouth Disease Virus to M Cells Enhances the Antigen-specific Systemic and Mucosal Immune Response.
    Kim SH; Lee HY; Jang YS
    Immune Netw; 2013 Aug; 13(4):157-62. PubMed ID: 24009543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. M cell-targeting strategy facilitates mucosal immune response and enhances protection against CVB3-induced viral myocarditis elicited by chitosan-DNA vaccine.
    Ye T; Yue Y; Fan X; Dong C; Xu W; Xiong S
    Vaccine; 2014 Jul; 32(35):4457-4465. PubMed ID: 24958702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. C5a receptor-targeting ligand-mediated delivery of dengue virus antigen to M cells evokes antigen-specific systemic and mucosal immune responses in oral immunization.
    Kim SH; Yang IY; Jang SH; Kim J; Truong TT; Van Pham T; Truong NU; Lee KY; Jang YS
    Microbes Infect; 2013 Nov; 15(13):895-902. PubMed ID: 23892099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Crossing the barrier: Targeting epithelial receptors for enhanced oral vaccine delivery.
    Devriendt B; De Geest BG; Goddeeris BM; Cox E
    J Control Release; 2012 Jun; 160(3):431-9. PubMed ID: 22353618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Roles of M cells in infection and mucosal vaccines.
    Wang M; Gao Z; Zhang Z; Pan L; Zhang Y
    Hum Vaccin Immunother; 2014; 10(12):3544-51. PubMed ID: 25483705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mucosal immunity and vaccination.
    Holmgren J
    FEMS Microbiol Immunol; 1991 Dec; 4(1):1-9. PubMed ID: 1815705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rational application of nanoadjuvant for mucosal vaccine delivery system.
    Dewangan HK
    J Immunol Methods; 2020; 481-482():112791. PubMed ID: 32387695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advancedoral vaccine delivery strategies for improving the immunity.
    Zhang Y; Li M; Du G; Chen X; Sun X
    Adv Drug Deliv Rev; 2021 Oct; 177():113928. PubMed ID: 34411689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nasal and pulmonary vaccine delivery using particulate carriers.
    Jia Y; Krishnan L; Omri A
    Expert Opin Drug Deliv; 2015 Jun; 12(6):993-1008. PubMed ID: 25952104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipid-Based Particles: Versatile Delivery Systems for Mucosal Vaccination against Infection.
    Corthésy B; Bioley G
    Front Immunol; 2018; 9():431. PubMed ID: 29563912
    [TBL] [Abstract][Full Text] [Related]  

  • 15. C5a receptor targeting of partial non-structural protein 3 of dengue virus promotes antigen-specific IFN-γ-producing T-cell responses in a mucosal dengue vaccine model.
    Kim SH; Kim YN; Kim J; Jang YS
    Cell Immunol; 2018 Mar; 325():41-47. PubMed ID: 29397905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Strategies for the induction of immune responses at mucosal surfaces making use of cholera toxin B subunit as immunogen, carrier, and adjuvant.
    Holmgren J; Czerkinsky C; Lycke N; Svennerholm AM
    Am J Trop Med Hyg; 1994; 50(5 Suppl):42-54. PubMed ID: 8203723
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel vaccine development strategies for inducing mucosal immunity.
    Fujkuyama Y; Tokuhara D; Kataoka K; Gilbert RS; McGhee JR; Yuki Y; Kiyono H; Fujihashi K
    Expert Rev Vaccines; 2012 Mar; 11(3):367-79. PubMed ID: 22380827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The mucosal immune system for vaccine development.
    Lamichhane A; Azegamia T; Kiyonoa H
    Vaccine; 2014 Nov; 32(49):6711-23. PubMed ID: 25454857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ISCOMATRIX™ adjuvant reduces mucosal tolerance for effective pulmonary vaccination against influenza.
    Timothy AA; Tokanovic A; Snibson KJ; Edwards SJ; Pearse MJ; Scheerlinck JP; Sutton P
    Hum Vaccin Immunother; 2015; 11(2):377-85. PubMed ID: 25692970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mucosal vaccines: a paradigm shift in the development of mucosal adjuvants and delivery vehicles.
    Srivastava A; Gowda DV; Madhunapantula SV; Shinde CG; Iyer M
    APMIS; 2015 Apr; 123(4):275-88. PubMed ID: 25630573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.